|34.21||-0.1100||-0.32%||Vol 416.88K||1Y Perf -45.77%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.79 2.31%|
|Target Price||46.00||Analyst Rating||Strong Buy 1.00|
|Potential %||34.46||Finscreener Ranking||★★★★+ — 58.12|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★★★ 56.08|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★+ 55.90|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||29.57||Earnings Rating||—|
|Market Cap||899.59M||Earnings Date||8th Aug 2022|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.57|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||365.29K|
|Avg. Monthly Volume||233.59K|
|Avg. Quarterly Volume||314.29K|
Castle Biosciences Inc. (NASDAQ: CSTL) stock closed at 34.21 per share at the end of the most recent trading day (a -0.32% change compared to the prior day closing price) with a volume of 416.88K shares and market capitalization of 899.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 135 people. Castle Biosciences Inc. CEO is Derek J. Maetzold.
The one-year performance of Castle Biosciences Inc. stock is -45.77%, while year-to-date (YTD) performance is -20.2%. CSTL stock has a five-year performance of %. Its 52-week range is between 15.58 and 78.585, which gives CSTL stock a 52-week price range ratio of 29.57%
Castle Biosciences Inc. currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 1.63, a price-to-sale (PS) ratio of 8.19, a price to cashflow ratio of 230.60, a PEG ratio of 2.32, a ROA of -11.71%, a ROC of -12.43% and a ROE of -12.66%. The company’s profit margin is -56.85%, its EBITDA margin is -55.90%, and its revenue ttm is $75.37 Million , which makes it $2.87 revenue per share.
Of the last four earnings reports from Castle Biosciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Castle Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Castle Biosciences Inc. is Strong Buy (1), with a target price of $46, which is +34.46% compared to the current price. The earnings rating for Castle Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Castle Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Castle Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.21, ATR14 : 2.46, CCI20 : 189.96, Chaikin Money Flow : 0.03, MACD : 2.36, Money Flow Index : 67.41, ROC : 25.22, RSI : 58.24, STOCH (14,3) : 83.01, STOCH RSI : 0.98, UO : 51.31, Williams %R : -16.99), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Castle Biosciences Inc. in the last 12-months were: Bernhard E. Spiess (Option Excercise at a value of $0), Daniel M. Bradbury (Option Excercise at a value of $0), Daniel M. Bradbury (Sold 159 080 shares of value $6 922 181 ), Derek J. Maetzold (Option Excercise at a value of $192 079), Derek J. Maetzold (Sold 65 236 shares of value $3 225 601 ), Ellen Goldberg (Option Excercise at a value of $0), Frank Stokes (Option Excercise at a value of $13 520), G. Bradley Cole (Option Excercise at a value of $0), Kimberlee Caple (Option Excercise at a value of $0), Kristen Oelschlager (Option Excercise at a value of $0), Mara Glickman Aspinall (Option Excercise at a value of $0), Miles D. Harrison (Option Excercise at a value of $0), Tobin W. Juvenal (Option Excercise at a value of $0)
Wed, 27 Jul 2022 03:30 GMT Castle Biosciences (CSTL) Receives a Buy from Robert W. Baird- TipRanks. All rights reserved.
Tue, 10 May 2022 12:47 GMT Castle Biosciences (CSTL) Receives a Buy from SVB Securities- TipRanks. All rights reserved.
Thu, 31 Mar 2022 06:57 GMT Castle Biosciences (CSTL) Receives a Buy from Leerink Partners- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.